太龙药业(600222.SH)：上半年净利润1934.66万元 同比下降27.32%

Core Viewpoint - Tailong Pharmaceutical (600222.SH) reported a decline in revenue and net profit for the first half of 2025, attributed to the uneven progress of national Chinese medicine procurement and increased tax expenses [1] Financial Performance - The company achieved an operating income of 762 million yuan, representing a year-on-year decrease of 17.77% [1] - The net profit attributable to shareholders of the listed company was 19.35 million yuan, down 27.32% year-on-year [1] Market Factors - The decline in sales was influenced by the participation of major products in the national Chinese medicine procurement, with sales not fully covering due to varying provincial approval timelines [1]